Bell Investment Advisors Inc Has $54,000 Stake in Amgen Inc. (NASDAQ:AMGN)

Bell Investment Advisors Inc lowered its position in Amgen Inc. (NASDAQ:AMGN) by 15.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 241 shares of the medical research company’s stock after selling 44 shares during the period. Bell Investment Advisors Inc’s holdings in Amgen were worth $54,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in AMGN. Veracity Capital LLC lifted its position in shares of Amgen by 3.3% in the second quarter. Veracity Capital LLC now owns 1,353 shares of the medical research company’s stock worth $300,000 after buying an additional 43 shares during the last quarter. All Terrain Financial Advisors LLC lifted its holdings in Amgen by 0.8% in the 1st quarter. All Terrain Financial Advisors LLC now owns 5,646 shares of the medical research company’s stock worth $1,365,000 after purchasing an additional 44 shares during the last quarter. JNBA Financial Advisors boosted its position in Amgen by 6.2% during the second quarter. JNBA Financial Advisors now owns 749 shares of the medical research company’s stock worth $166,000 after purchasing an additional 44 shares during the period. Park National Corp OH grew its holdings in Amgen by 1.8% during the second quarter. Park National Corp OH now owns 2,614 shares of the medical research company’s stock valued at $580,000 after purchasing an additional 45 shares during the last quarter. Finally, Revolve Wealth Partners LLC raised its position in shares of Amgen by 0.3% in the second quarter. Revolve Wealth Partners LLC now owns 17,286 shares of the medical research company’s stock valued at $3,838,000 after purchasing an additional 45 shares during the period. 74.44% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Amgen

In other news, EVP Jonathan P. Graham sold 10,000 shares of the stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $272.81, for a total transaction of $2,728,100.00. Following the sale, the executive vice president now owns 28,078 shares in the company, valued at $7,659,959.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Jonathan P. Graham sold 10,000 shares of the stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $272.81, for a total transaction of $2,728,100.00. Following the sale, the executive vice president now directly owns 28,078 shares of the company’s stock, valued at $7,659,959.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Amgen Inc acquired 1,764,705 shares of the company’s stock in a transaction that occurred on Tuesday, September 19th. The stock was bought at an average price of $17.00 per share, with a total value of $29,999,985.00. Following the transaction, the insider now directly owns 35,368,653 shares in the company, valued at $601,267,101. The disclosure for this purchase can be found here. Corporate insiders own 0.57% of the company’s stock.

Amgen Price Performance

Shares of NASDAQ AMGN traded up $5.19 during midday trading on Tuesday, reaching $271.88. 165,739 shares of the company traded hands, compared to its average volume of 2,466,032. Amgen Inc. has a 12 month low of $211.71 and a 12 month high of $291.60. The company has a debt-to-equity ratio of 7.71, a quick ratio of 2.56 and a current ratio of 2.86. The stock’s 50-day simple moving average is $268.38 and its 200-day simple moving average is $246.53. The firm has a market cap of $145.50 billion, a PE ratio of 18.95, a PEG ratio of 2.55 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, October 31st. The medical research company reported $4.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.65 by $0.31. The firm had revenue of $6.90 billion during the quarter, compared to the consensus estimate of $6.92 billion. Amgen had a net margin of 28.20% and a return on equity of 165.37%. The firm’s quarterly revenue was up 3.7% on a year-over-year basis. During the same period last year, the firm posted $4.70 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 18.65 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Friday, November 17th will be given a dividend of $2.13 per share. The ex-dividend date of this dividend is Thursday, November 16th. This represents a $8.52 dividend on an annualized basis and a yield of 3.13%. Amgen’s dividend payout ratio (DPR) is presently 60.55%.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Barclays upped their price objective on shares of Amgen from $210.00 to $230.00 in a report on Monday, October 2nd. Mizuho lifted their price target on Amgen from $214.00 to $223.00 and gave the stock a “neutral” rating in a research report on Monday, August 14th. Morgan Stanley reduced their price objective on Amgen from $300.00 to $291.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 1st. Royal Bank of Canada upped their target price on shares of Amgen from $253.00 to $256.00 and gave the company a “sector perform” rating in a research note on Wednesday, November 1st. Finally, UBS Group decreased their price target on shares of Amgen from $272.00 to $268.00 and set a “neutral” rating on the stock in a research report on Thursday, November 2nd. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $278.15.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.